Agents and methods for treating CBP-dependent cancers
AssigneeMemoral Sloan Kettering Cancer Center
InventorsAlex Kentsis, Kavitha Ramaswamy, Lauren Marek
Life of this patent
Estimating the term…
Abstract
Single chain peptides comprising either a cell penetrating HIV-TAT peptide sequence and a MYB:CBP complex interfering peptide sequence from MYB, or compsiring a cell penetrating HIV-TAT peptide sequence, a CBP binding peptide sequence from CREB and a MYB:CBP complex interfering peptide sequence from MYB, are provided for use in preventing MYB:CBP complex formation and downstream events leading to cancer, in particular a leukemia. Both L-amino acid single chain peptides and retro-inverso single chain peptides are provided.
Claims7
A method for treating leukemia, lymphoma, colon cancer, breast cancer, adenoid cystic carcinoma, brain cancer or a dysproliferative disease associated with a MYB dysregulation in a patient in need thereof, wherein the method comprises administering to said patient a therapeutically effective amount of a single chain peptide consisting of D-amino acids and comprising:
- an N-terminal portion comprising the amino acid sequence selected from KLENETSMLLLELEKIRK (SEQ ID NO:19) and KLENETSMLLLEL (SEQ ID NO:24);
- a C-terminal portion comprising the amino acid sequence RRRQRRKKRGY (SEQ ID NO:17);
- and the amino acid sequence therebetween selected from PADSSLDNLIKRYpSPRRSLIERR (SEQ ID NO:33), KRYpSPRRSLIERR (SEQ ID NO:23), and PADSSLDNLIKRYpS (SEQ ID NO:34).
Dependencies are inferred from the claim text.